Advertisement

Familial Cancer

, Volume 7, Issue 2, pp 179–186 | Cite as

Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers

  • Ashley D. Staton
  • Allison W. Kurian
  • Kristin Cobb
  • Meredith A. Mills
  • James M. FordEmail author
Article

Abstract

Background Women with mutations in the BRCA1 or BRCA2 cancer susceptibility genes face unique choices regarding management of their high risk for breast and ovarian cancer that impact their reproductive options. In order to explore women’s preferences for management of elevated cancer risk, we evaluated the decisions of BRCA1/2 mutation carriers about contraception, prophylactic surgery, and family planning. Methods An internet-based questionnaire assessing high-risk women’s preferences about cancer risk management and reproductive options was designed, pilot-tested and administered electronically to 284 participants of an internet-based advocacy group for women with BRCA1/2 mutations. Results Two hundred and thirteen eligible participants completed the majority of the survey. Mean age was 34 years; 66% were BRCA1 mutation carriers and 34% were BRCA2 mutation carriers. Most women (92%) had used oral contraceptive pills. About 88% of responders reported frequent or extreme worry about transmitting the mutation to their children. Despite their high level of worry, few responders said they would likely consider using assisted reproduction technologies such as a pregnancy surrogate (3%), cryopreservation of oocytes or embryos (8%), or pre-implantation genetic diagnosis (PGD) to select embryos without BRCA1/2 mutations (13%). Conclusions Although they expressed substantial concern about transmitting BRCA1/2 mutations to their children, only a minority of the high-risk women surveyed were likely to consider currently available assisted reproductive strategies. Further research is necessary to explore the risk management preferences of patients with inherited cancer predisposition, and to incorporate these preferences into clinical care.

Keywords

BRCA1/2 Breast cancer Ovarian cancer Pre-implantation genetic diagnosis Prophylactic mastectomy Prophylactic oophorectomy 

Abbreviations

PGD

Pre-implantation genetic diagnosis

PO

Prophylactic bilateral salpingo-oophorectomy

PM

Prophylactic mastectomy

STAI

State-trait anxiety inventory

IES

Impact of event scale

IRB

Institutional review board

OCPs

Oral contraceptive pills

Notes

Acknowledgement

The authors gratefully acknowledge the assistance of Sue Friedman, DVM, in distributing the questionnaire through the FORCE website.

References

  1. 1.
    Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130PubMedCrossRefGoogle Scholar
  2. 2.
    Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329–1333PubMedCrossRefGoogle Scholar
  3. 3.
    Metcalfe KA, Snyder C, Seidel J et al (2005) The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer 4:97–103PubMedCrossRefGoogle Scholar
  4. 4.
    Cullinane CA, Lubinski J, Neuhausen SL et al (2005) Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer 117:988–991PubMedCrossRefGoogle Scholar
  5. 5.
    Friedman LC, Kramer RM (2005) Reproductive issues for women with BRCA mutations. J Natl Cancer Inst Monogr 34:83–86PubMedCrossRefGoogle Scholar
  6. 6.
    Jernstrom H, Lubinski J, Lynch HT et al (2004) Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 96:1094–1098PubMedCrossRefGoogle Scholar
  7. 7.
    Narod SA, Dube MP, Klijn J et al (2002) Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94:1773–1779PubMedGoogle Scholar
  8. 8.
    Narod SA, Offit K (2005) Prevention and management of hereditary breast cancer. J Clin Oncol 23:1656–1663PubMedCrossRefGoogle Scholar
  9. 9.
    National Comprehensive Cancer Network. Genetic/familial High-risk Assessment: Breast and Ovarian CancerGoogle Scholar
  10. 10.
    Narod SA, Brunet JS, Ghadirian P et al (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study hereditary breast cancer clinical study group. Lancet 356:1876–1881PubMedCrossRefGoogle Scholar
  11. 11.
    Gronwald J, Tung N, Foulkes WD et al (2006) Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 118:2281–2284PubMedCrossRefGoogle Scholar
  12. 12.
    Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71PubMedCrossRefGoogle Scholar
  13. 13.
    Offit K, Kohut K, Clagett B et al (2006) Cancer genetic testing and assisted reproduction. J Clin Oncol 24:4775–4782PubMedCrossRefGoogle Scholar
  14. 14.
    Lodder LN, Frets PG, Trijsburg RW et al (2000) Attitudes towards termination of pregnancy in subjects who underwent presymptomatic testing for the BRCA1/BRCA2 gene mutation in the Netherlands. J Med Genet 37:883–884PubMedCrossRefGoogle Scholar
  15. 15.
    Wagner TM, Ahner R (1998) Prenatal testing for late-onset diseases such as mutations in the breast cancer gene 1 (BRCA1). Just a choice or a step in the wrong direction? Hum Reprod 13:1125–1126PubMedCrossRefGoogle Scholar
  16. 16.
    Lancaster JM, Wiseman RW, Berchuck A (1996) An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene. Obstet Gynecol 87:306–309PubMedCrossRefGoogle Scholar
  17. 17.
    Menon U, Harper J, Sharma A et al (2007) Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. Hum Reprod 22:1573–1577PubMedCrossRefGoogle Scholar
  18. 18.
    Partridge AH, Gelber S, Peppercorn J et al (2004) Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 22:4174–4183PubMedCrossRefGoogle Scholar
  19. 19.
    Friedman S (2005) FORCE: facing our risk of cancer empowered. Available at www.facingourrisk.org. Accessed April 3 2007Google Scholar
  20. 20.
    Kurian AW, Hartman AR, Mills MA et al (2005) Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. Health Expect 8:221–233PubMedCrossRefGoogle Scholar
  21. 21.
    Spielberger CD, Gorsuch RL, Lushene RD (1970) Manual for the state-trait anxiety inventory (self-evaluation questionnaire). Consulting Psychologists Press, Palo Alto, CAGoogle Scholar
  22. 22.
    Horowitz M, Wilner N, Alvarez W (1979) Impact of event scale: a measure of subjective stress. Psychosom Med 41:209–218PubMedGoogle Scholar
  23. 23.
    Silvera SA, Miller AB, Rohan TE (2005) Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: a prospective cohort study. Cancer Causes Control 16:1059–1063PubMedCrossRefGoogle Scholar
  24. 24.
    Bensyl DM, Iuliano DA, Carter M et al (2005) Contraceptive use—United States and territories, behavioral risk factor surveillance system, 2002. MMWR Surveill Summ 54:1–72PubMedGoogle Scholar
  25. 25.
    Milne RL, Knight JA, John EM et al (2005) Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 14:350–356PubMedCrossRefGoogle Scholar
  26. 26.
    Friedenson B (2001) A current perspective on genetic testing for breast and ovarian cancer: the oral contraceptive decision. MedGenMed 3:2PubMedGoogle Scholar
  27. 27.
    McLaughlin JR, Risch HA, Lubinski J et al (2007) Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 8:26–34PubMedCrossRefGoogle Scholar
  28. 28.
    McInerney-Leo A, Biesecker BB, Hadley DW et al (2004) BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention. Am J Med Genet A 130:221–227CrossRefGoogle Scholar
  29. 29.
    Vadaparampil ST, Ropka M, Stefanek ME (2005) Measurement of psychological factors associated with genetic testing for hereditary breast, ovarian and colon cancers. Fam Cancer 4:195–206PubMedCrossRefGoogle Scholar
  30. 30.
    Calzone KA, Prindiville SA, Jourkiv O et al (2005) Randomized comparison of group versus individual genetic education and counseling for familial breast and/or ovarian cancer. J Clin Oncol 23:3455–3464PubMedCrossRefGoogle Scholar
  31. 31.
    Croyle RT, Smith KR, Botkin JR et al (1997) Psychological responses to BRCA1 mutation testing: preliminary findings. Health Psychol 16:63–72PubMedCrossRefGoogle Scholar
  32. 32.
    Spielberger CD, Vagg PR, Barker LR et al (1983) Manual for the state-trait anxiety inventory (FormY). Mind Garden, Redwood City, CAGoogle Scholar
  33. 33.
    Thewes B, Meiser B, Hickie IB (2001) Psychometric properties of the impact of event scale amongst women at increased risk for hereditary breast cancer. Psychooncology 10:459–468PubMedCrossRefGoogle Scholar
  34. 34.
    Spits C, De Rycke M, Van Ranst N et al (2007) Preimplantation genetic diagnosis for cancer predisposition syndromes. Prenat Diagn 27:447–456PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2007

Authors and Affiliations

  • Ashley D. Staton
    • 1
  • Allison W. Kurian
    • 1
    • 2
  • Kristin Cobb
    • 2
  • Meredith A. Mills
    • 1
  • James M. Ford
    • 1
    Email author
  1. 1.Department of MedicineStanford University School of MedicineStanfordUSA
  2. 2.Department of Health Research and PolicyStanford University School of MedicineStanfordUSA

Personalised recommendations